Takeda Pharmaceutical Company Limited (LON:0A87)

Market Cap	34.92B
Revenue (ttm)	23.68B
Net Income (ttm)	557.84M
Shares Out	n/a
EPS (ttm)	0.35
PE Ratio	62.61
Forward PE	n/a
Dividend	0.44 (2.93%)
Ex-Dividend Date	Mar 31, 2025

Volume	157
Average Volume	1,990
Open	15.38
Previous Close	n/a
Day's Range	15.38 - 15.38
52-Week Range	12.82 - 15.38
Beta	n/a
RSI	69.45
Earnings Date	Jul 30, 2025

About LON:0A87

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 47,455
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A87

Financial Performance

In 2024, LON:0A87's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY